This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive
compensation for actions taken through them.
The Ebola scare in 2014 was resounding within the health care sector, and many biotechs found themselves developing vaccines and related drugs in an effort to be first to market. If any single firm was able to capitalize on this, its valuation would have been through the roof. However as fears have subsided, the development of a vaccine or related drugs has been put on the back burner for most, but one biotech made waves in the market Monday morning.
OraSure Technologies Inc. (NASDAQ: OSUR) announced that it received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick Ebola Rapid Antigen Test for use with fingerstick and venous whole blood.
Note that this test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories and facilities adequately equipped, trained and capable of testing for Ebola infection.
Douglas A. Michels, president and CEO of OraSure, said:
The OraQuick Rapid Ebola Antigen Test is an easy to use, rapid test, that we believe will be a critical tool in containing and controlling current outbreaks of the Ebola virus. We are grateful to the FDA for working closely with us throughout the EUA process to expedite deployment of our test.
ALSO READ: 3 Biotech Stocks to Buy With Huge Catalysts Coming Soon
Separately, a vaccine being developed by NewLink Genetics Corp. (NASDAQ: NLNK) and Merck & Co. Inc. (NYSE: MRK) was shown to be 100% effective in preventing Ebola, according to an interim look from a late-stage study in Guinea. However, the results still must be confirmed.
Will Merck and NewLink go the route of taking this as a commercial opportunity? According to Merck Vaccines’ Mark Feinberg in a telephone interview that is not the case, CNBC reported.
Interestingly enough, good news surrounding an Ebola vaccine might spell bad news for specialty suit maker, Lakeland Industries Inc. (NASDAQ: LAKE). However this company is up over 13% in just the past quarter alone.
Arbutus Biopharma Corp. (NASDAQ: ABUS), formerly known as Tekmira, stepped out of the Ebola arena and is now focusing on hepatitis B. The company began trading under its new name and ticker Monday morning.
Shares of OraSure were up 2.6% to $5.07 Monday morning. The stock has a consensus analyst price target of $9.43 and a 52-week trading range of $4.42 to $10.93.
NewLink shares were down 1.6% to $51.33, in a 52-week trading range of $17.32 to $58.73. The consensus analyst price target is $59.75.
ALSO READ: 7 Analyst Stock Picks Under $10 With Huge Upside Calls
Shares of Merck were near flat at $58.95, in a 52-week trading range of $52.49 to $63.62. The consensus price target is $65.29.
Lakeland shares were down 1.2% at $10.38. The consensus price target is $19.00 and the 52-week trading range is $5.50 to $29.55.
Shares of Arbutus were down 3.4% at $10.46.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.